Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...

Diffuse systemic sclerosis (dSSc) can be a devastating disease, and to date there are no clearly beneficial treatments. However, the agent relaxin has shown some promise in improving skin disease. [1] ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

A 65-year-old woman with diffuse scleroderma presented with increasing dyspnea on exertion, fatigue, and approximately a six-week history of palpitations. She had a history of scleroderma-related ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a ...

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...